1-16 of 16
Elaine K. Allan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

BGB324 Represents an Axl and BCR-ABL1 Inhibitor with Activity in the T315I Mutant

Robert Erdmann, PhDMSc, Heather Jorgensen, PhD, Isabel Ben-Batalla, PhD, Nils Kruse, PhD, David Micklem, PhD, Gunhild von Amsberg, MD, Philippe Schafhausen, MD, Alexander Schultze, MD MSc, Mark Wroblewski, MSc, Mascha Binder, Miguel Cubas-Cordova, MSc, Tobias Hadlich, MD, Melanie Janning, MD MSc, Stefanie Sawall, Victoria Gensch, Elaine K Allan, Leena Mukherjee, PhD, Heather Morrison, BSc, Jennifer Cassells, Nicolaus Kroeger, MD, James Lorens, MD, Richard E. Clark, MD, Steffen Koschmieder, MD, Peter Vandenberghe, MD PhD, Tim H. Brümmendorf, MD, Andreas Hochhaus, MD, Peter Carmeliet, MD PhD, Tessa L. Holyoake, MD PhD, Klaus Pantel, MD PhD, Carsten Bokemeyer, MD, Sonja Loges, MD PhD
Journal: Blood
Blood (2014) 124 (21): 4512.
https://doi.org/10.1182/blood.V124.21.4512.4512
Published: 2014
Journal Articles

Axl Represents a Therapeutic Target In T315I-Mutated and WT Chronic Myeloid Leukemia

Robert Erdmann, PhD MSc, Heather Jorgensen, PhD, Alexander Schultze, MD, MSc, Gunhild von Amsberg, MD, Isabel Ben-Battala, PhD, MSc, Mark Wroblewski, MSc, Miguel Cubas Cordova, MSc, Stefanie Sawall, Victoria Witzke, Elaine K Allan, Leena Mukherjee, PhD, Heather Morrison, Jennifer Cassels, Philippe Schafhausen, MD, Nicolaus Kroeger, MD, James Lorens, MD, Richard E. Clark, MBBS, MD, FRCP, FRCPath, Peter Vandenberghe, MD, PhD, Tim H. Brümmendorf, MD, Andreas Hochhaus, MD, Peter Carmeliet, MD, PhD, Klaus Pantel, MD, PhD, Carsten Bokemeyer, MD, Tessa L. Holyoake, PhD, FRCP, FRCPath, Sonja Loges, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 1469.
https://doi.org/10.1182/blood.V122.21.1469.1469
Published: 2013
Journal Articles

Autocrine TNF-α production supports CML stem and progenitor cell survival and enhances their proliferation

Brief Report
Paolo Gallipoli, Francesca Pellicano, Heather Morrison, Kamilla Laidlaw, Elaine K. Allan, Ravi Bhatia, Mhairi Copland, Heather G. Jørgensen, Tessa L. Holyoake
Journal: Blood
Blood (2013) 122 (19): 3335–3339.
https://doi.org/10.1182/blood-2013-02-485607
Published: 2013
Includes: Supplemental data
Journal Articles

Inhibition of Autophagy in Combination with Ponatinib or Dual PI3K/mTOR Inhibition to Improve Treatment Response for Both Bcr-Abl Dependent and Independent Mechanisms of TKI-Resistance in CML

G.Vignir Helgason, PhD, Elaine K Allan, Samanta Mariani, Arunima Mukhopadhyay, Maria Karvela, Sara Galavotti, Alessandra Audia, Ashley Hamilton, Franck E. Nicolini, MD, PhD, Brian J. Druker, Paolo Salomoni, Bruno Calabretta, Tessa L. Holyoake, PhD, FRCP, FRCPath
Journal: Blood
Blood (2012) 120 (21): 1664.
https://doi.org/10.1182/blood.V120.21.1664.1664
Published: 2012
Journal Articles

Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival

Ashley Hamilton, G. Vignir Helgason, Mirle Schemionek, Bin Zhang, Svetlana Myssina, Elaine K. Allan, Franck E. Nicolini, Carsten Müller-Tidow, Ravi Bhatia, Valerie G. Brunton, Steffen Koschmieder, Tessa L. Holyoake
Journal: Blood
Blood (2012) 119 (6): 1501–1510.
https://doi.org/10.1182/blood-2010-12-326843
Published: 2012
Includes: Supplemental data
Journal Articles

Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells

Nicholas B. Heaney, Francesca Pellicano, Bin Zhang, Lisa Crawford, Su Chu, Syed M. A. Kazmi, Elaine K. Allan, Heather G. Jorgensen, Alexandra E. Irvine, Ravi Bhatia, Tessa L. Holyoake
Journal: Blood
Blood (2010) 115 (11): 2241–2250.
https://doi.org/10.1182/blood-2008-06-164582
Published: 2010
Includes: Supplemental data
Journal Articles

Combination of the Hedgehog Pathway Inhibitor LDE225 and Nilotinib Eliminates Chronic Myeloid Leukemia Stem and Progenitor Cells.

David A Irvine, roMB, ChB, Bin Zhang, MD, PhD, Elaine K Allan, BSc, Tessa L Holyoake, PhD, MB, ChB, FRCP, FRCPath, FRSE, Marion Dorsch, PhD, Paul W Manley, PhD, Ravi Bhatia, MD, PhD, Mhairi Copland, PhD, BSc, MB, ChB, MRCP, FRCPath
Journal: Blood
Blood (2009) 114 (22): 1428.
https://doi.org/10.1182/blood.V114.22.1428.1428
Published: 2009
Journal Articles

BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors

Mhairi Copland, Francesca Pellicano, Linda Richmond, Elaine K. Allan, Ashley Hamilton, Francis Y. Lee, Roberto Weinmann, Tessa L. Holyoake
Journal: Blood
Blood (2008) 111 (5): 2843–2853.
https://doi.org/10.1182/blood-2007-09-112573
Published: 2008
Includes: Supplemental data
Journal Articles

Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34 + CML cells

Brief Report
Heather G. Jørgensen, Elaine K. Allan, Niove E. Jordanides, Joanne C. Mountford, Tessa L. Holyoake
Journal: Blood
Blood (2007) 109 (9): 4016–4019.
https://doi.org/10.1182/blood-2006-11-057521
Published: 2007
Journal Articles

BMS-214662 Eliminates CML Stem Cells and Is Active Against Blast Crisis CML and Cells Expressing BCR-ABL Kinase Mutations.

Mhairi Copland, MD, Linda Richmond, BSc, Ashley Hamilton, BSc, Elaine K. Allan, BSc, Junia V. Melo, MD, PhD, Tessa L. Holyoake, MD, PhD
Journal: Blood
Blood (2006) 108 (11): 739.
https://doi.org/10.1182/blood.V108.11.739.739
Published: 2006
Journal Articles

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

Mhairi Copland, Ashley Hamilton, Lucy J. Elrick, Janet W. Baird, Elaine K. Allan, Niove Jordanides, Martin Barow, Joanne C. Mountford, Tessa L. Holyoake
Journal: Blood
Blood (2006) 107 (11): 4532–4539.
https://doi.org/10.1182/blood-2005-07-2947
Published: 2006
Journal Articles

BMS-214662 Targets Quiescent Chronic Myeloid Leukaemia Stem Cells and Enhances the Activity of Both Imatinib and Dasatinib (BMS-354825).

Mhairi Copland, MD, Ashley Hamilton, BSc, Elaine K. Allan, BSc, Valerie Brunton, PhD, Tessa L. Holyoake, MD, PhD
Journal: Blood
Blood (2005) 106 (11): 693.
https://doi.org/10.1182/blood.V106.11.693.693
Published: 2005
Journal Articles

Dasatinib (BMS-354825) Has Increased Activity Against Bcr-Abl Compared to Imatinib in Primary CML Cells In Vitro , but Does Not Eradicate Quiescent CML Stem Cells.

Mhairi Copland, MD, Ashley Hamilton, BSc, Janet W. Baird, PhD, Martin Barow, PhD, Elaine K. Allan, BSc, Lucy J. Elrick, PhD, Tessa L. Holyoake, MD, PhD
Journal: Blood
Blood (2005) 106 (11): 695.
https://doi.org/10.1182/blood.V106.11.695.695
Published: 2005
Journal Articles

G-CSF as a Potent Mitogen Augments the Elimination of CML Stem Cells by Imatinib Mesylate In Vitro .

Heather G. Jorgensen, PhD MRPharmS, Mhairi Copland, MD, Elaine K. Allan, BSc(Hons), Allen C. Eaves, MD PhD, Connie J. Eaves, PhD, Xiaoyan Jiang, MD PhD, Tessa L. Holyoake, MD PhD
Journal: Blood
Blood (2004) 104 (11): 2941.
https://doi.org/10.1182/blood.V104.11.2941.2941
Published: 2004
Journal Articles

Enhanced Primary CML Stem Cell Elimination by Bryostatin Priming with Imatinib Mesylate In Vitro .

Heather G. Jorgensen, PhD, MRPharmS, Elaine K. Allan, BSc (Hons), Joanne C. Mountford, PhD, Linda Richmond, BSc(Hons), Moira A. Elliott, PhD, MRPharmS, Tessa L. Holyoake, MD, PhD
Journal: Blood
Blood (2004) 104 (11): 1997.
https://doi.org/10.1182/blood.V104.11.1997.1997
Published: 2004
Journal Articles

α 1 -Acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571

Brief Report
Heather G. Jørgensen, Moira A. Elliott, Elaine K. Allan, Christine E. Carr, Tessa L. Holyoake, Kevin D. Smith
Journal: Blood
Blood (2002) 99 (2): 713–715.
https://doi.org/10.1182/blood.V99.2.713
Published: 2002